A new patent has been awarded to James Sherley for a very unusual method claimed for making induced pluripotent stem (iPS) cells. The patent, No. 8,759,098, claims that a single non-genetic chemical agent, xanthine, can by itself reprogram adult stem cells (ASC) into iPS cells (aka iPSCs; see image they released at left). Surprising patent, huh? Another […]
Sherley patent for reprogramming method like STAP cells Read More »
Is Neuralstem flirting with noncompliance via a Right To Try Law in Colorado? Colorado is an independent-minded state. For example, it is one of only a few states including Washington State with legalized marijuana use. More recently, Colorado passed a new law supported by the ultra-conservative Goldwater Institute, the so-called Right To Try Law. This law
Neuralstem flirting with noncompliance via Right To Try Law? Read More »
There is more good news from leading stem cell biotech Advanced Cell Technology (ACT) on preclinical rodent studies using stem cells to treat mice with an MS-like condition. They published a new paper in the journal Stem Cell Reports entitled “Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of
Advanced Cell Technology (ACT) Revs Up Pre-Clinical Studies for MS Read More »
ISSCR and I held a short essay contest for a free registration to ISSCR 2014 in Vancouver. The winning piece was written by student Mohamed Gatie, but there was a great 2nd place essay by Sherry Hikita that deserved acknowledgment. I’m publishing that essay below and Sherry will be receiving a free signed copy of my book and a free stem cell
Great 2nd Place ISSCR Essay Related to Vision and Stem Cells Read More »
Late last year I was hearing some exciting things about California Stem Cell, Inc. under the leadership of Hans Keirstead. (2020 update: interestingly 3 years ago Keirstead ran for congress, but the campaign didn’t quite make it.) In fact, I thought a big move for California Stem was in the cards for 2014 and looking into
As Predicted, Big News For California Stem Cell, Inc.: Purchased by NeoStem Read More »
Very small embryonic-like stem cells aka VSELs are reported to be tiny adult stem cells that are pluripotent or non-existent depending on whom you talk to most recently or which paper you just read. These very controversial cells (which I once compared to the Sasquatch) have a wildly fluctuating history with their existence on multiple occasions
Wild History of VSELs Predicts Future of STAP Cells? Read More »
Stem cell biotech, Advanced Cell Technology (ACT; stock symbol ACTC), has started off 2014 with indications that it is in a phase of rapid evolution. Some changes, such as today’s announced departure of now former CEO Gary Rabin (see my 2013 interview with him here), are already in the public domain, but other big developments
Big Changes Unfolding at Advanced Cell Technology (ACTC) Read More »
Big Pharma Giant Johnson & Johnson (J & J; $JNJ) announced today a $12.5 million investment in stem cells & regenerative medicine via the small biotech Capricor ($CAPR) and the potential for the bet to go into the hundreds of millions for the heart disease program. It was only 8 days ago that I made
J&J Bets Up to $325 million on Capricor: Big Pharma Stem Cell Move as Predicted for 2014 Read More »
Each year I make predictions for the stem cell field for the coming year. In today’s post I write about my top 10 stem cell predictions for 2014. You can see my predictions for 2013 here (see predictions for 2011 and 2012 predictions, which are kind of fun to read to see what was on the “mind” of the field
Stem Cell Predictions for 2014 Read More »
I’ve added a fun and helpful new feature on the right side bar of the blog in the form of a stem cell biotech stock ticker. The ticker is for some of the most widely held stem and cellular medicine companies. A sample screen shot is shown in this post. Quite a few stem cell-related
New Stem Cell Stock Ticker Read More »